Positive allosteric modulation of α4β2 nicotinic receptors potentiates some CNS effects of the α4β2 agonist, ABT-594

被引：0

作者：

Franklin, S. R. ^{[1
]}

Mohler, E. G. ^{[1
]}

Komater, V. A. ^{[1
]}

Robb, H. ^{[1
]}

Radek, R. J. ^{[1
]}

Rustay, N. R. ^{[1
]}

Brown, J. W. ^{[1
]}

Gopalakrishnan, M. ^{[1
]}

Decker, M. W. ^{[1
]}

Rueter, L. E. ^{[1
]}

机构：

[1] Abbott Labs, Global Pharmaceut Res & Dev, Neurosci Res, Abbott Pk, IL 60064 USA

来源：

BIOCHEMICAL PHARMACOLOGY | 2009年 / 78卷 / 07期

关键词：

D O I：

10.1016/j.bcp.2009.06.083

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：921 / 921

页数：1

共 50 条

[31] Correction to: Desformylflustrabromine, a positive allosteric modulator of α4β2-containing nicotinic acetylcholine receptors, enhances cognition in rats
Agnieszka Nikiforuk
Ewa Litwa
Martyna Krawczyk
Piotr Popik
Hugo Arias
Pharmacological Reports, 2020, 72 : 1078 - 1078
[32] Agonist and antagonist effects of tobacco-related nitrosamines on human α4β2 nicotinic acetylcholine receptors
Brusco, Simone
Ambrosi, Paola
Meneghini, Simone
Becchetti, Andrea
FRONTIERS IN PHARMACOLOGY, 2015, 6
[33] ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]:: A novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors:: II.: In vivo characterization
Bannon, AW
Decker, MW
Curzon, P
Buckley, MJ
Kim, DJB
Radek, RJ
Lynch, JK
Wasicak, JT
Lin, NH
Arnold, WH
Holladay, MW
Williams, M
Arneric, SP
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 285 (02): : 787 - 794
[34] Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration
Xiu Liu
Psychopharmacology, 2013, 230 : 203 - 213
[35] Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration
Liu, Xiu
PSYCHOPHARMACOLOGY, 2013, 230 (02) : 203 - 213
[36] Non-equivalent Ligand Selectivity of Agonist Sites in (α4β2)2α4 Nicotinic Acetylcholine Receptors A KEY DETERMINANT OF AGONIST EFFICACY
Mazzaferro, Simone
Gasparri, Federica
New, Karina
Alcaino, Constanza
Faundez, Manuel
Iturriaga Vasquez, Patricio
Vijayan, Ranjit
Biggin, Philip C.
Bermudez, Isabel
JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (31) : 21795 - 21806
[37] Non-Equivalent Ligand Selectivity of Agonist Sites in (α4β2) 2α4 Nicotinic Acetylcholine Receptors: A Key Determinant of Agonist Efficacy
Mazzaferro, Simone
Gasparri, Federica
New, Karina
Alcaino, Constanza
Bermudez, Isabel
BIOPHYSICAL JOURNAL, 2015, 108 (02) : 429A - 429A
[38] Insights Into the Differential Desensitization of a4#2 Nicotinic Acetylcholine Receptor Isoforms Obtained With Positive Allosteric Modulation of Mutant ReceptorsS
Papke, Roger L.
Stokes, Clare
MOLECULAR PHARMACOLOGY, 2023, 103 (02) : 63 - 76
[39] The Unique α4(+)/(-) a4 Agonist Binding Site in (α4)3(β2)2 Subtype Nicotinic Acetylcholine Receptors Permits Differential Agonist Desensitization Pharmacology versus the α4)2(β2)73 Subtypes
Eaton, J. Brek
Lucero, Linda M.
Stratton, Harrison
Chang, Yongchang
Cooper, John F.
Lindstrom, Jon M.
Lukas, Ronald J.
Whiteaker, Paul
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 348 (01): : 46 - 58
[40] In vivo characterization of the co-administration of α4β2 neuronal nicotinic receptor agonist and positive allosteric modulator in experimental pain in rats
Zhu, Chang Z.
Chin, Chih-liang
Zhong, Chengmin
Mikusa, Joe
Chandran, Prasant
Salyers, Anita
Wensink, Erica
Silmer, Gricelda
Lewis, La Geisha
Gauvin, Donna
Baker, Scott
Tovcimak, Ann
Brown, Jordan
Rustay, Nathan
Fox, Gerard B.
Decker, Michael W.
Lee, Chih-Hung
Gopalakrishnan, Murali
Honore, Prisca
BIOCHEMICAL PHARMACOLOGY, 2009, 78 (07) : 920 - 920

← 1 2 3 4 5 →